Exclusive special offer and discount title banner vector image

GLOBAL OPHTHALMIC DRUGS MARKET FORECAST 2023-2032

SCOPE OF THE REPORT

Ophthalmic Drugs Market by Indication (Dry Eye, Glaucoma, Infection/inflammation/allergies, Retinal Disorder, Other Indications) Market by Type (Prescription Drugs, Over-the-counter Drugs) Market by Dosage Form (Gels, Eye Solutions & Suspensions, Capsules & Tablets, Eye Drops, Ointments) Market by Therapeutic Class (Anti-glaucoma, Anti-infection, Anti-inflammatory, Anti-allergy, Other Therapeutic Classes) Market by Distribution Channel (Hospital Pharmacies, Drug Stores, Online Pharmacies, Other Distribution Channels) by Geography

REQUEST FREE SAMPLE

MARKET OVERVIEW

The global ophthalmic drugs market was valued at $36147.47 million in 2022 and is expected to reach $66508.62 million by 2032, growing at a CAGR of 6.09% during the forecast period, 2023-2032.

An aging global population is a significant contributor to the ophthalmic drugs market growth as age-related eye disorders become more prevalent, raising the demand for ophthalmic drugs. Also, advancements in drug delivery technologies have revolutionized treatment options, offering patients more effective and convenient therapeutic solutions.

Further, the rising number of diabetes cases worldwide is another major growth driver, given its association with diabetic retinopathy and macular edema, necessitating ophthalmic drug usage. Moreover, heightened awareness about eye health and regular check-ups has led to early disease detection, boosting the demand for ophthalmic drugs.

Ophthalmic Drugs Market

Read our latest blog on the Ophthalmic Drugs Market

GROWTH ENABLERS

Key growth enablers of the global ophthalmic drugs market are:

  • Aging population’s susceptibility to age-related eye conditions
    • The aging population is more susceptible to age-related eye conditions due to biological, physiological, and environmental factors. These changes increase the risk of developing various eye conditions, leading to vision impairment, and in some cases, irreversible vision loss.
    • With advancing age, cells throughout the body, including those in the eyes, undergo natural changes. The eye’s tissues, such as the retina, lens, and cornea, experience a decreased cell density and function. Additionally, the ability of cells to repair themselves becomes less efficient, making the eyes more vulnerable to damage caused by environmental factors and cumulative oxidative stress.
    • As people age, they may develop other health conditions such as diabetes and hypertension. These systemic health factors can directly or indirectly affect the eyes, leading to diabetic retinopathy, hypertensive retinopathy, and other eye-related complications.
    • Moreover, older adults are recommended regular eye examinations, as many age-related eye conditions are more effectively managed when detected early. Lifestyle choices, such as a balanced diet, not smoking, protecting the eyes from UV light, and managing systemic health conditions, can also significantly preserve eye health as people age.
  • Advancements in drug delivery technologies
  • Rising prevalence of eye diseases and disorders
  • Favorable reimbursement policies by healthcare systems

GROWTH RESTRAINTS

Key growth restraints of the global ophthalmic drugs market are:

  • Delay in drug approvals
  • Side effects related to ophthalmic drugs
    • The use of ophthalmic drugs, like all medications, can be associated with various side effects. These can range from mild & transient to severe & long-lasting, depending on the drug and individual patient factors.
    • Allergic reactions to ophthalmic drugs are possible but relatively rare. Symptoms of an allergic reaction may include severe eye redness, swelling, itching, or difficulty breathing. If any signs of an allergic reaction occur, immediate medical attention is necessary.
    • Further, certain eye medications can lead to either dryness or increased tear production. Dryness may occur due to the composition of the drug or as a side effect of preservatives in eye drops.

To Know More About This Report, Request a Free Sample Copy

KEY MARKET TRENDS

Global Ophthalmic Drugs Market | Key Market Trends

  • With the introduction of innovative therapies and drug formulations, the management of dry eye syndrome has become more effective, boosting market growth.
  • Patients and healthcare providers are increasingly opting for combination therapies that address multiple eye conditions simultaneously, nudging the market for combination ophthalmic drugs.
  • There is a noticeable trend toward OTC ophthalmic drugs as they provide convenient access to treatments, positively impacting market revenue.
  • Pharmaceutical companies are investing in R&D activities to develop novel ophthalmic drugs, including gene therapies and biologics, offering promising growth prospects.

MARKET SEGMENTATION

Market Segmentation – Indication, Type, Dosage Form, Therapeutic Class, and Distribution Channel –

Market by Indication:

  • Dry Eye
  • Glaucoma
  • Infection/Inflammation/Allergies
  • Retinal Disorder
    • Wet Age-Related Macular Degeneration
    • Dry Age-Related Macular Degeneration
    • Diabetic Retinopathy
    • Other Retinal Disorders
  • Other Indications

Market by Type

  • Prescription Drugs
    • Prescription drugs are the largest revenue-generating type.
    • Prescription-based ophthalmic drugs are specifically formulated for eye-related conditions. They need a valid prescription from a licensed eye care professional, such as an ophthalmologist or optometrist. These drugs are used to treat a wide range of eye conditions and diseases. Accordingly, they require careful evaluation, diagnosis, and monitoring by an eye care specialist to ensure safe and effective usage.
    • Prescription-based ophthalmic drugs come in various forms, including eye drops, ointments, gels, and intraocular injections. They are designed to be applied directly to the eyes to deliver the medication locally to the affected tissues, minimizing systemic side effects.
  • Over-The-Counter Drugs

Market by Dosage Form:

  • Gels
  • Eye Solutions & Suspensions
  • Capsules & Tablets
  • Eye Drops
    • Eye drops are the fastest-growing dosage form in the global ophthalmic drugs market.
    • Eye drops are one of the most common and convenient ways to deliver medications to the eye, providing targeted therapy to the affected area and offering rapid onset of action. Ophthalmic eye drops are a type of liquid ophthalmic dosage form designed to be instilled directly into the eye to treat various eye conditions.
    • Ophthalmic eye drops consist of active pharmaceutical ingredients (APIs) dissolved or suspended in a sterile, aqueous liquid vehicle. The liquid vehicle is usually a water-based solution or saline solution, making it compatible with sensitive ocular tissues.
    • Eye drops are formulated and manufactured under strict aseptic conditions to ensure their sterility, reducing the risk of infection when applied to the eye. The pH and osmolarity of eye drops are carefully adjusted to be compatible with the ocular environment, ensuring minimal irritation and maintaining eye comfort.
  • Ointments

Market by Therapeutic Class:

  • Anti-Glaucoma
  • Anti-Infection
  • Anti-Inflammatory
  • Anti-Allergy
  • Other Therapeutic Classes

Market by Distribution Channel:

  • Hospital Pharmacies
  • Drug Stores
  • Online Pharmacies
  • Other Distribution Channels

GEOGRAPHICAL STUDY

Geographical Study based on Four Major Regions:
  • North America: The United States and Canada
    • North America is the largest revenue-generating region in the global ophthalmic drugs market.
    • The rising prevalence of age-related eye conditions, such as cataracts, glaucoma, and macular degeneration, along with lifestyle factors contributing to conditions like dry eye syndrome, is driving the demand for ophthalmic drugs in North America.
    • Ophthalmic drug manufacturers are investing heavily in research and development to introduce novel and effective treatments for various eye diseases. This focus on R&D is expanding the portfolio of available ophthalmic drugs in the market.
    • Increased awareness about eye health and the availability of eye care services are encouraging early diagnosis and treatment of eye diseases. This trend is contributing to the growth of the ophthalmic drugs market in North America.
  • Europe: The United Kingdom, Germany, France, Italy, Spain, Belgium, Poland, and Rest of Europe
  • Asia-Pacific: China, Japan, India, South Korea, Indonesia, Thailand, Vietnam, Australia & New Zealand, and Rest of Asia-Pacific
  • Rest of World: Latin America, the Middle East & Africa

MAJOR PLAYERS

The major players in the global ophthalmic drugs market are:

  • AbbVie Inc
  • Bausch Health Companies Inc
  • Genentech Inc
  • Johnson & Johnson
  • Thea Pharma Inc
  • Novartis AG
  • Pfizer Inc

Key strategies adopted by some of these companies:

  • June 2023: Bausch + Lomb Corporation, a subsidiary of Bausch Health Companies Inc, entered into a definitive agreement with Novartis to acquire XIIDRA® (Lifitegrast ophthalmic solution) 5%, a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease (DED) focusing on inflammation associated with dry eye along with Libvatrep and AcuStream from Novartis.
  • March 2023: Santen Pharmaceutical Co Ltd announced the filing of an application for the manufacturing and marketing approval of STN1011402 ophthalmic cream (generic name: epinastine hydrochloride) in Japan, which can treat allergic conjunctivitis that is applied once daily to the periocular area (upper and lower eyelids).
  • February 2023: AbbVie and Capsida Biotherapeutics Inc announced an expanded strategic collaboration to develop genetic medicines for eye diseases with high unmet needs. AbbVie’s extensive capabilities will be paired with Capsida’s novel adeno-associated virus (AAV) engineering platform and manufacturing capability to identify and advance three programs.

REPORT SYNOPSIS

REPORT SCOPEDETAILS
Market Forecast Years2023-2032
Base Year2022
Market Historical Years2018-2022
Forecast UnitsRevenue ($ Million)
Segments AnalyzedTherapeutic Class, Dosage Form, Type, Indication, Distribution Channel
Geographies AnalyzedNorth America, Europe, Asia-Pacific, and Rest of World
Companies Analyzed

AbbVie Inc, Accutome Inc, Bausch Health Companies Inc, Genentech Inc, Johnson & Johnson, Thea Pharma Inc, Novartis AG, Pfizer Inc, Regeneron Pharmaceuticals Inc, Santen Pharmaceutical Co Ltd, Sun Pharmaceutical Industries Ltd, Teva Pharmaceuticals Industries Ltd

TABLE OF CONTENT

  1. RESEARCH SCOPE & METHODOLOGY
    1. STUDY OBJECTIVES
    2. METHODOLOGY
    3. ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    1. MARKET SIZE & ESTIMATES
    2. MARKET OVERVIEW
    3. SCOPE OF STUDY
    4. CRISIS SCENARIO ANALYSIS
      1. IMPACT OF COVID-19 ON OPHTHALMIC DRUGS MARKET
    5. MAJOR MARKET FINDINGS
      1. EMERGING THERAPIES FOR DRY EYE SYNDROME
      2. GROWING DEMAND FOR COMBINATION THERAPIES
      3. INCREASING INVESTMENT IN RESEARCH & DEVELOPMENT
      4. SHIFT TOWARD OVER-THE-COUNTER (OTC) PRODUCTS
  3. MARKET DYNAMICS
    1. KEY DRIVERS
      1. AGING POPULATION’S SUSCEPTIBILITY TO AGE-RELATED EYE CONDITIONS
      2. ADVANCEMENTS IN DRUG DELIVERY TECHNOLOGIES
      3. RISING PREVALENCE OF EYE DISEASES AND DISORDERS
      4. FAVORABLE REIMBURSEMENT POLICIES BY HEALTHCARE SYSTEMS
    2. KEY RESTRAINTS
      1. DELAY IN DRUG APPROVALS
      2. SIDE EFFECTS RELATED TO OPHTHALMIC DRUGS
  4. KEY ANALYTICS
    1. KEY MARKET TRENDS
    2. TECHNOLOGY SNAPSHOT
      1. BIOLOGICS
      2. CELL THERAPY
      3. GENE THERAPY
      4. DRUG DELIVERY
      5. SMALL MOLECULE
      6. OTHER TECHNOLOGIES
    3. PORTER’S FIVE FORCES ANALYSIS
      1. BUYERS POWER
      2. SUPPLIERS POWER
      3. SUBSTITUTION
      4. NEW ENTRANTS
      5. INDUSTRY RIVALRY
    4. GROWTH PROSPECT MAPPING
      1. GROWTH PROSPECT MAPPING FOR UNITED STATES
      2. GROWTH PROSPECT MAPPING FOR ITALY
      3. GROWTH PROSPECT MAPPING FOR INDIA
      4. GROWTH PROSPECT MAPPING FOR THE MIDDLE EAST & AFRICA
    5. MARKET MATURITY ANALYSIS
    6. MARKET CONCENTRATION ANALYSIS
    7. KEY BUYING CRITERIA
    8. REGULATORY FRAMEWORK
  5. MARKET BY INDICATION
    1. DRY EYE
    2. GLAUCOMA
    3. INFECTION/INFLAMMATION/ALLERGIES
    4. RETINAL DISORDER
      1. WET AGE-RELATED MACULAR DEGENERATION
      2. DRY AGE-RELATED MACULAR DEGENERATION
      3. DIABETIC RETINOPATHY
      4. OTHER RETINAL DISORDERS
    5. OTHER INDICATIONS
  6. MARKET BY TYPE
    1. PRESCRIPTION DRUGS
    2. OVER-THE-COUNTER DRUGS
  7. MARKET BY DOSAGE FORM
    1. GELS
    2. EYE SOLUTIONS & SUSPENSIONS
    3. CAPSULES & TABLETS
    4. EYE DROPS
    5. OINTMENTS
  8. MARKET BY THERAPEUTIC CLASS
    1. ANTI-GLAUCOMA
    2. ANTI-INFECTION
    3. ANTI-INFLAMMATORY
    4. ANTI-ALLERGY
    5. OTHER THERAPEUTIC CLASSES
  9. MARKET BY DISTRIBUTION CHANNEL
    1. HOSPITAL PHARMACIES
    2. DRUG STORES
    3. ONLINE PHARMACIES
    4. OTHER DISTRIBUTION CHANNELS
  10. GEOGRAPHICAL ANALYSIS
    1. NORTH AMERICA
      1. MARKET SIZE & ESTIMATES
      2. NORTH AMERICA OPHTHALMIC DRUGS MARKET DRIVERS
      3. NORTH AMERICA OPHTHALMIC DRUGS MARKET CHALLENGES
      4. KEY PLAYERS IN NORTH AMERICA OPHTHALMIC DRUGS MARKET
      5. COUNTRY ANALYSIS
        1. UNITED STATES
          1. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
        2. CANADA
          1. CANADA OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
    2. EUROPE
      1. MARKET SIZE & ESTIMATES
      2. EUROPE OPHTHALMIC DRUGS MARKET DRIVERS
      3. EUROPE OPHTHALMIC DRUGS MARKET CHALLENGES
      4. KEY PLAYERS IN EUROPE OPHTHALMIC DRUGS MARKET
      5. COUNTRY ANALYSIS
        1. UNITED KINGDOM
          1. UNITED KINGDOM OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
        2. GERMANY
          1. GERMANY OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
        3. FRANCE
          1. FRANCE OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
        4. ITALY
          1. ITALY OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
        5. SPAIN
          1. SPAIN OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
        6. BELGIUM
          1. BELGIUM OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
        7. POLAND
          1. POLAND OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
        8. REST OF EUROPE
          1. REST OF EUROPE OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
    3. ASIA-PACIFIC
      1. MARKET SIZE & ESTIMATES
      2. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET DRIVERS
      3. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET CHALLENGES
      4. KEY PLAYERS IN ASIA-PACIFIC OPHTHALMIC DRUGS MARKET
      5. COUNTRY ANALYSIS
        1. CHINA
          1. CHINA OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
        2. JAPAN
          1. JAPAN OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
        3. INDIA
          1. INDIA OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
        4. SOUTH KOREA
          1. SOUTH KOREA OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
        5. INDONESIA
          1. INDONESIA OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
        6. THAILAND
          1. THAILAND OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
        7. VIETNAM
          1. VIETNAM OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
        8. AUSTRALIA & NEW ZEALAND
          1. AUSTRALIA & NEW ZEALAND OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
        9. REST OF ASIA-PACIFIC
          1. REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
    4. REST OF WORLD
      1. MARKET SIZE & ESTIMATES
      2. REST OF WORLD OPHTHALMIC DRUGS MARKET DRIVERS
      3. REST OF WORLD OPHTHALMIC DRUGS MARKET CHALLENGES
      4. KEY PLAYERS IN REST OF WORLD OPHTHALMIC DRUGS MARKET
      5. REGIONAL ANALYSIS
        1. LATIN AMERICA
          1. LATIN AMERICA OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
        2. MIDDLE EAST & AFRICA
          1. MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
  11. COMPETITIVE LANDSCAPE
    1. KEY STRATEGIC DEVELOPMENTS
      1. MERGERS & ACQUISITIONS
      2. PRODUCT LAUNCHES & DEVELOPMENTS
      3. PARTNERSHIPS & AGREEMENTS
    2. COMPANY PROFILES
      1. ABBVIE INC
        1. COMPANY OVERVIEW
        2. PRODUCTS & SERVICES
        3. STRENGTHS & CHALLENGES
      2. ACCUTOME INC
        1. COMPANY OVERVIEW
        2. PRODUCTS & SERVICES
        3. STRENGTHS & CHALLENGES
      3. BAUSCH HEALTH COMPANIES INC
        1. COMPANY OVERVIEW
        2. PRODUCTS & SERVICES
        3. STRENGTHS & CHALLENGES
      4. GENENTECH INC
        1. COMPANY OVERVIEW
        2. PRODUCTS & SERVICES
        3. STRENGTHS & CHALLENGES
      5. JOHNSON & JOHNSON
        1. COMPANY OVERVIEW
        2. PRODUCTS & SERVICES
        3. STRENGTHS & CHALLENGES
      6. THEA PHARMA INC
        1. COMPANY OVERVIEW
        2. PRODUCTS & SERVICES
        3. STRENGTHS & CHALLENGES
      7. NOVARTIS AG
        1. COMPANY OVERVIEW
        2. PRODUCTS & SERVICES
        3. STRENGTHS & CHALLENGES
      8. PFIZER INC
        1. COMPANY OVERVIEW
        2. PRODUCTS & SERVICES
        3. STRENGTHS & CHALLENGES
      9. REGENERON PHARMACEUTICALS INC
        1. COMPANY OVERVIEW
        2. PRODUCTS & SERVICES
        3. STRENGTHS & CHALLENGES
      10. SANTEN PHARMACEUTICAL CO LTD
        1. COMPANY OVERVIEW
        2. PRODUCTS & SERVICES
        3. STRENGTHS & CHALLENGES
      11. SUN PHARMACEUTICAL INDUSTRIES LTD
        1. COMPANY OVERVIEW
        2. PRODUCTS & SERVICES
        3. STRENGTHS & CHALLENGES
      12. TEVA PHARMACEUTICALS INDUSTRIES LTD
        1. COMPANY OVERVIEW
        2. PRODUCTS & SERVICES
        3. STRENGTHS & CHALLENGES

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT – OPHTHALMIC DRUGS

TABLE 2: REGULATORY FRAMEWORK

TABLE 3: GLOBAL OPHTHALMIC DRUGS MARKET, BY INDICATION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 4: GLOBAL OPHTHALMIC DRUGS MARKET, BY INDICATION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 5: GLOBAL DRY EYE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 6: GLOBAL DRY EYE MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 7: GLOBAL GLAUCOMA MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 8: GLOBAL GLAUCOMA MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 9: GLOBAL INFECTION/INFLAMMATION/ALLERGIES MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 10: GLOBAL INFECTION/INFLAMMATION/ALLERGIES MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 11: GLOBAL RETINAL DISORDER MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 12: GLOBAL RETINAL DISORDER MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 13: GLOBAL OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 14: GLOBAL OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 15: GLOBAL WET AGE-RELATED MACULAR DEGENERATION MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 16: GLOBAL WET AGE-RELATED MACULAR DEGENERATION MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 17: GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 18: GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 19: GLOBAL DIABETIC RETINOPATHY MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 20: GLOBAL DIABETIC RETINOPATHY MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 21: GLOBAL OTHER RETINAL DISORDERS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 22: GLOBAL OTHER RETINAL DISORDERS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 23: GLOBAL OTHER INDICATIONS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 24: GLOBAL OTHER INDICATIONS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 25: GLOBAL OPHTHALMIC DRUGS MARKET, BY TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 26: GLOBAL OPHTHALMIC DRUGS MARKET, BY TYPE, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 27: GLOBAL PRESCRIPTION DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 28: GLOBAL PRESCRIPTION DRUGS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 29: GLOBAL OVER-THE-COUNTER DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 30: GLOBAL OVER-THE-COUNTER DRUGS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 31: GLOBAL OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 32: GLOBAL OPHTHALMIC DRUGS MARKET, BY DOSAGE FORM, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 33: GLOBAL GELS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 34: GLOBAL GELS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 35: GLOBAL EYE SOLUTIONS & SUSPENSIONS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 36: GLOBAL EYE SOLUTIONS & SUSPENSIONS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 37: GLOBAL CAPSULES & TABLETS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 38: GLOBAL CAPSULES & TABLETS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 39: GLOBAL EYE DROPS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 40: GLOBAL EYE DROPS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 41: GLOBAL OINTMENTS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 42: GLOBAL OINTMENTS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 43: GLOBAL OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 44: GLOBAL OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC CLASS, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 45: GLOBAL ANTI-GLAUCOMA MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 46: GLOBAL ANTI-GLAUCOMA MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 47: GLOBAL ANTI-INFECTION MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 48: GLOBAL ANTI-INFECTION MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 49: GLOBAL ANTI-INFLAMMATORY MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 50: GLOBAL ANTI-INFLAMMATORY MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 51: GLOBAL ANTI-ALLERGY MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 52: GLOBAL ANTI-ALLERGY MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 53: GLOBAL OTHER THERAPEUTIC CLASSES MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 54: GLOBAL OTHER THERAPEUTIC CLASSES MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 55: GLOBAL OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 56: GLOBAL OPHTHALMIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 57: GLOBAL HOSPITAL PHARMACIES MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 58: GLOBAL HOSPITAL PHARMACIES MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 59: GLOBAL DRUG STORES MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 60: GLOBAL DRUG STORES MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 61: GLOBAL ONLINE PHARMACIES MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 62: GLOBAL ONLINE PHARMACIES MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 63: GLOBAL OTHER DISTRIBUTION CHANNELS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 64: GLOBAL OTHER DISTRIBUTION CHANNELS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 65: GLOBAL OPHTHALMIC DRUGS MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 66: GLOBAL OPHTHALMIC DRUGS MARKET, BY GEOGRAPHY, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 67: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 68: NORTH AMERICA OPHTHALMIC DRUGS MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 69: KEY PLAYERS OPERATING IN NORTH AMERICA OPHTHALMIC DRUGS MARKET

TABLE 70: EUROPE OPHTHALMIC DRUGS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 71: EUROPE OPHTHALMIC DRUGS MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 72: KEY PLAYERS OPERATING IN EUROPE OPHTHALMIC DRUGS MARKET

TABLE 73: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 74: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 75: KEY PLAYERS OPERATING IN ASIA-PACIFIC OPHTHALMIC DRUGS MARKET

TABLE 76: REST OF WORLD OPHTHALMIC DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 77: REST OF WORLD OPHTHALMIC DRUGS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 78: KEY PLAYERS OPERATING IN REST OF WORLD OPHTHALMIC DRUGS MARKET

TABLE 79: LIST OF MERGERS & ACQUISITIONS

TABLE 80: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

TABLE 81: LIST OF PARTNERSHIPS & AGREEMENTS

LIST OF FIGURES

FIGURE 1: KEY MARKET TRENDS

FIGURE 2: PORTER’S FIVE FORCES ANALYSIS

FIGURE 3: GROWTH PROSPECT MAPPING FOR UNITED STATES

FIGURE 4: GROWTH PROSPECT MAPPING FOR ITALY

FIGURE 5: GROWTH PROSPECT MAPPING FOR INDIA

FIGURE 6: GROWTH PROSPECT MAPPING FOR THE MIDDLE EAST & AFRICA

FIGURE 7: MARKET MATURITY ANALYSIS

FIGURE 8: MARKET CONCENTRATION ANALYSIS

FIGURE 9: GLOBAL OPHTHALMIC DRUGS MARKET, GROWTH POTENTIAL, BY INDICATION, IN 2022

FIGURE 10: GLOBAL OPHTHALMIC DRUGS MARKET, BY DRY EYE, 2023-2032 (IN $ MILLION)

FIGURE 11: GLOBAL OPHTHALMIC DRUGS MARKET, BY GLAUCOMA, 2023-2032 (IN $ MILLION)

FIGURE 12: GLOBAL OPHTHALMIC DRUGS MARKET, BY INFECTION/INFLAMMATION/ALLERGIES, 2023-2032 (IN $ MILLION)

FIGURE 13: GLOBAL OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, 2023-2032 (IN $ MILLION)

FIGURE 14: GLOBAL OPHTHALMIC DRUGS MARKET, GROWTH POTENTIAL, BY RETINAL DISORDER, IN 2022

FIGURE 15: GLOBAL OPHTHALMIC DRUGS MARKET, BY WET AGE-RELATED MACULAR DEGENERATION, 2023-2032 (IN $ MILLION)

FIGURE 16: GLOBAL OPHTHALMIC DRUGS MARKET, BY DRY AGE-RELATED MACULAR DEGENERATION, 2023-2032 (IN $ MILLION)

FIGURE 17: GLOBAL OPHTHALMIC DRUGS MARKET, BY DIABETIC RETINOPATHY, 2023-2032 (IN $ MILLION)

FIGURE 18: GLOBAL OPHTHALMIC DRUGS MARKET, BY OTHER RETINAL DISORDERS, 2023-2032 (IN $ MILLION)

FIGURE 19: GLOBAL OPHTHALMIC DRUGS MARKET, BY OTHER INDICATIONS, 2023-2032 (IN $ MILLION)

FIGURE 20: GLOBAL OPHTHALMIC DRUGS MARKET, GROWTH POTENTIAL, BY TYPE, IN 2022

FIGURE 21: GLOBAL OPHTHALMIC DRUGS MARKET, BY PRESCRIPTION DRUGS, 2023-2032 (IN $ MILLION)

FIGURE 22: GLOBAL OPHTHALMIC DRUGS MARKET, BY OVER-THE-COUNTER DRUGS, 2023-2032 (IN $ MILLION)

FIGURE 23: GLOBAL OPHTHALMIC DRUGS MARKET, GROWTH POTENTIAL, BY DOSAGE FORM, IN 2022

FIGURE 24: GLOBAL OPHTHALMIC DRUGS MARKET, BY GELS, 2023-2032 (IN $ MILLION)

FIGURE 25: GLOBAL OPHTHALMIC DRUGS MARKET, BY EYE SOLUTIONS & SUSPENSIONS, 2023-2032 (IN $ MILLION)

FIGURE 26: GLOBAL OPHTHALMIC DRUGS MARKET, BY CAPSULES & TABLETS, 2023-2032 (IN $ MILLION)

FIGURE 27: GLOBAL OPHTHALMIC DRUGS MARKET, BY EYE DROPS, 2023-2032 (IN $ MILLION)

FIGURE 28: GLOBAL OPHTHALMIC DRUGS MARKET, BY OINTMENTS, 2023-2032 (IN $ MILLION)

FIGURE 29: GLOBAL OPHTHALMIC DRUGS MARKET, GROWTH POTENTIAL, BY THERAPEUTIC CLASS, IN 2022

FIGURE 30: GLOBAL OPHTHALMIC DRUGS MARKET, BY ANTI-GLAUCOMA, 2023-2032 (IN $ MILLION)

FIGURE 31: GLOBAL OPHTHALMIC DRUGS MARKET, BY ANTI-INFECTION, 2023-2032 (IN $ MILLION)

FIGURE 32: GLOBAL OPHTHALMIC DRUGS MARKET, BY ANTI-INFLAMMATORY, 2023-2032 (IN $ MILLION)

FIGURE 33: GLOBAL OPHTHALMIC DRUGS MARKET, BY ANTI-ALLERGY, 2023-2032 (IN $ MILLION)

FIGURE 34: GLOBAL OPHTHALMIC DRUGS MARKET, BY OTHER THERAPEUTIC CLASSES, 2023-2032 (IN $ MILLION)

FIGURE 35: GLOBAL OPHTHALMIC DRUGS MARKET, GROWTH POTENTIAL, BY DISTRIBUTION CHANNEL, IN 2022

FIGURE 36: GLOBAL OPHTHALMIC DRUGS MARKET, BY HOSPITAL PHARMACIES, 2023-2032 (IN $ MILLION)

FIGURE 37: GLOBAL OPHTHALMIC DRUGS MARKET, BY DRUG STORES, 2023-2032 (IN $ MILLION)

FIGURE 38: GLOBAL OPHTHALMIC DRUGS MARKET, BY ONLINE PHARMACIES, 2023-2032 (IN $ MILLION)

FIGURE 39: GLOBAL OPHTHALMIC DRUGS MARKET, BY OTHER DISTRIBUTION CHANNELS, 2023-2032 (IN $ MILLION)

FIGURE 40: NORTH AMERICA OPHTHALMIC DRUGS MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN %)

FIGURE 41: UNITED STATES OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 42: CANADA OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 43: EUROPE OPHTHALMIC DRUGS MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN %)

FIGURE 44: UNITED KINGDOM OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 45: GERMANY OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 46: FRANCE OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 47: ITALY OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 48: SPAIN OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 49: BELGIUM OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 50: POLAND OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 51: REST OF EUROPE OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 52: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN %)

FIGURE 53: CHINA OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 54: JAPAN OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 55: INDIA OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 56: SOUTH KOREA OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 57: INDONESIA OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 58: THAILAND OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 59: VIETNAM OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 60: AUSTRALIA & NEW ZEALAND OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 61: REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 62: REST OF WORLD OPHTHALMIC DRUGS MARKET, REGIONAL OUTLOOK, 2022 & 2032 (IN %)

FIGURE 63: LATIN AMERICA OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)

FIGURE 64: MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET, 2023-2032 (IN $ MILLION)

FAQ’s

FAQs

The global ophthalmic drugs market size witnessed a downfall of around 16.82% in 2020.

Over-the-counter drugs are the fastest-growing type in the global ophthalmic drugs market, with a CAGR of 6.47%.

The growing interest in topical ophthalmic drugs and a significant rise in approval of novel ophthalmic therapeutics are the key market trends driving the market growth.

Request Customization
Request Customization